Search Results

from
 
  

Patent
number
Title of the invention and abstract piece Date of publication of the patent
1 TW201110979A
CANCER METASTASIS INHIBITOR

For the purpose of determining whether or not the activation of hepatic NF-kB is involved in the onset of metastatic tumors, a liver metastatic model induced in the spleen is used. When IKKss is lacked in both hepatocytes and hematopoietically-derived cells, the onset of tumors is remarkably decreased. A tumor cell activates an adjacent bone marrow cell (Kupffer cell) to produce a mitogen such as ...

01.04.2011
2 TW201110980A
COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.

01.04.2011
3 TW201110981A
COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.

01.04.2011
4 TW201110982A
OSTEOPONTIN ANTIBODIES

The present disclosure provides isolated antibodies, particularly human antibodies, or antigen binding portions thereof, that bind to osteopontin with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical ...

01.04.2011
5 TW201110983A
HUMANIZED ANTI-CDCP1 ANTIBODIES

The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

01.04.2011
6 TW201110984A
NANOPARTICLE DELIVERY VEHICLE

A nanoparticle delivery vehicle includes a nanoparticle, an active compound, and a phosphodiester moiety connecting the nanoparticle and the active compound and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active compound and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism a...

01.04.2011
7 TW201110985A
PHARMACEUTICAL COMPOSITIONS FOR TREATING TUMORS AND USE THEREOF

This present disclosure relates to pharmaceutical compositions for treating tumors using a polymeric micelle encapsulating an anti-tumor drug. The polymeric micelle comprises block copolymers comprising at least one hydrophilic block, at least one hydrophobic block, and at least one zwitterion. The present disclosure also relates to methods of enhancing the solubility of such drugs, methods of inc...

01.04.2011
8 TW201110986A
NOVEL CONJUGATES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to a binding agent to which is attached at least one cryptophycin derivative of formula (I): in which: R1 represents a halogen atom and R2 represents a group -OH, an acyl group derived from an amino acid AA or a group (C1-C4)alkanoyloxy; or alternatively R1 and R2 together form an epoxide unit; AA denotes a natural or unnatural amino acid; R3 represents a group (C1-C6)alkyl; ...

01.04.2011
9 TW201110987A
LIGAND AND METAL COMPLEX FOR PREPARING A BLOOD POOL AND TARGETING CONTRAST AGENT

The present invention provides a ligand of formula (I): the definitions of the substituted groups in formula (I) are defined as set forth in the specification and claim. The present invention also provides a stable metal complex for preparing a blood pool contrast agent or a targeting contrast agent.

01.04.2011
10 TW201110988A
LIGAND AND METAL COMPLEX FOR PREPARING A MRI CONTRAST AGENT

A ligand of a formula (I): X represents a single bond, methylene, 1, 1-cyclobutylene, 1, 1-cyclopentylene or 1, 1-cyclohexylene; each of A1, A2 and A3 represents hydrogen, a C1 to C3 alkyl group, a C1 to C3 phenylalkyl group, a C1 to C3 methoxyphenylalkyl group, diphenylmethyl or a C1 to C3 isothiocyanato phenylalkyl group; and R represents an aromatic ring, which may be chelated with a copper ion...

01.04.2011
11 TW201110989A
EXTERNALLY-USED PREPARATION BASED ON NITROGEN MONOXIDE FOR CURING SURROUNDING BLOOD VESSEL LESION OF DIABETES AND ITS PREPARATION METHOD

The present invention provides an externally-used preparation based on nitrogen monoxide for curing surrounding blood vessel lesion of diabetes and its preparation method, which uses the nitrate or the plant extract of nitrate as the nitrogen agent of the raw material and uses the organic acid or inorganic acid as the acid agent of the raw material. When the two agents jointly acts on the illness ...

01.04.2011
12 TW201110990A
OIL-IN-WATER TYPE EMULSION COMPOSITION

The present invention relates to an oil-in-water type emulsion composition and a sun-care cosmetic cosmetic material, wherein the oil-in-water type emulsion composition is characterized by containing the following (a)-(j): (a) Octocrylene, (b) bis-ethylhexyloxyphenol methoxyphenyl triazine, (c) diethylamino hydroxybenzoyl hexyl benzoate, (d) 4-tert-butyl-4'-methoxydibenzoyl methane, (e) water-solu...

01.04.2011
13 TW201110991A
WATER-IN-OIL TYPE EMULSIFIED SKIN COSMETICS

Disclosed is a skin cosmetic in which the emulsion stability can be ensured even when the skin cosmetic is prepared by adding a volatile hydrocarbon oil to a water-in-oil-type emulsion composition containing a non-volatile silicone oil, and which has an excellent non-oily sensation upon application. Specifically disclosed is a water-in-oil-type emulsion skin cosmetic which is characterized by comp...

01.04.2011
14 TW201110992A
EXTERNAL PREPARATION FOR SKIN

Disclosed is an external preparation for skin that has a pH of 3.0-6.0 and that combines (A) a higher alcohol, (B) 0.01-5 mass% of a long-chain acylsulfonate anionic surfactant represented by the belowmentioned general formula (1) such as a stearoyl methyl taurate, and (C) 0.1-5 mass% of tranexamic acid. R1CO-a-(CH2)nSO3M1 (1) (R1CO- is a saturated or unsaturated fatty acid residue having an avera...

01.04.2011
15 TW201110993A
HAIRDRESSING COSMETIC

Disclosed is a hair-dressing cosmetic which exerts good hair-dressing effect and good hair-redressing effect, although being water-based and having a low viscosity, shows no stickiness and high smoothness, and gives the sense of a light finish. Specifically disclosed is a hair-dressing cosmetic, comprising: (a) a polyalkylene glycol polymer (a1) or a sugar alcohol (a2), both being in a solid state...

01.04.2011
16 TW201110994A
HAIR DRESSING COSMETIC

Disclosed is a hair-dressing cosmetic which exerts good hair-dressing effect and hair-redressing effect, although being water-based and having a low viscosity, shows no stickiness and high smoothness and gives the sense of a favorable light finish. Specifically disclosed is a hair-dressing cosmetic containing (a) 0.1-10 mass% of a pressure-sensitive adhesive resin, and (b) 3-30 mass% of one or mor...

01.04.2011
17 TW201110995A
ORAL COMPOSITION FOR ALLEVIATION OF ULTRAVIOLET RADIATION-INDUCED DAMAGE

Disclosed are: an oral composition for alleviating ultraviolet radiation-induced damage, which can be used on a daily basis and is stable and safe; and a medicinal agent, an anti-wrinkle agent and a food composition, each of which comprises the oral composition. Specifically disclosed is an oral composition for alleviating ultraviolet radiation-induced damage, which comprises at least one compound...

01.04.2011
18 TW201110996A
BORINIC COMPOSITIONS

A stabilized oral care composition comprising a borinic acid derivative, e.g., a borinic ester.

01.04.2011
19 TW201110997A
LAMININ-332 PRODUCTION ACCELERATING COMPOSITION

Disclosed is a novel composition which has a function of accelerating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production accelerating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives of D-alanine or D-hydroxyproline and/or salts of...

01.04.2011
20 TW201110998A
HAIR DRESSING COSMETIC

Disclosed is a hair-dressing cosmetic which exerts good hair-dressing effect and hair-redressing effect, although having a low viscosity, shows no stickiness and high smoothness and gives the sense of a favorable light finish. Specifically disclosed is a hair-dressing cosmetic containing (a) 0.1-10 mass% of a pressure-sensitive adhesive resin, and (b) 0.01-20 mass% of an oily component, characteri...

01.04.2011